Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC)

StatusActive, Not Recruiting
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 1 year 11 months later Dec 2025 → Dec 2027
See other at-risk trials from Rgenta Therapeutics Inc

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion dates pushed to Dec 2027 Show 5 more changesShow less
    • Enrollment closed, study ongoing
    • Interventions modified
    • Trial arms changed: 3 → 9
    • Study sites: 10 to 9
    • Eligibility criteria expanded, about 57 words
  2. Site contacts updated at 1 of 10 sitesv10
  3. Study sites: 9 to 10v9
  4. Study sites: 7 to 9v8
  5. Study sites: 5 to 7v7
Show 5 earlier versionsHide 5 earlier versions
  1. Study sites: 3 to 5v6
  2. Start date changed from estimate of Aug 2024 to Aug 19, 2024
    • Site details revised at 1 of 3 sites
    v5
  3. Start date: Jun 2024 to Aug 2024
    • Study sites: 2 to 3
    v4
  4. Trial status: Not Yet Recruiting to Recruiting
    • Site details revised at 2 of 2 sites
    v3
  5. Study sites: 1 to 2v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Phase 1 study to evaluate safety, tolerability and anti-tumor activity of RGT-61159 in patients with ACC or CRC
Trial Details
NCT Number NCT06462183
Lead Sponsor Rgenta Therapeutics Inc
Conditions
(from sponsor)		 Adenoid Cystic Carcinoma, Colorectal Cancer
Related terms Carcinoma, Adenoid Cystic, Colorectal Neoplasms
Enrollment 105 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov